Abvc Biopharma (ABVC) Liabilities and Shareholders Equity (2010 - 2026)

Abvc Biopharma (ABVC) has reported Liabilities and Shareholders Equity for 16 consecutive years, with $19.4 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Liabilities and Shareholders Equity rose 152.94% year-over-year to $19.4 million; the trailing twelve-month figure through Jun 2026 stood at $81.4 million (up 115.01% YoY), and the FY2025 full-year result was $21.1 million, up 179.34% from the prior year.
• Liabilities and Shareholders Equity retreated to $19.4 million in Q2 2026 per ABVC's latest filing, from $19.7 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $21.2 million in Q3 2025 and bottomed at $7.4 million in Q3 2023.
• Historically, Liabilities and Shareholders Equity has averaged $12.0 million across 5 years, with a median of $10.0 million in 2022.
• The sharpest annual moves came in 2023 and 2025: Liabilities and Shareholders Equity sank 32.38% in 2023, then jumped 179.34% in 2025.
• Over 5 years, Liabilities and Shareholders Equity stood at $9.6 million in 2022, then declined by 18.74% to $7.8 million in 2023, then declined by 3.14% to $7.5 million in 2024, then soared by 179.34% to $21.1 million in 2025, then fell by 7.89% to $19.4 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $19.4 million, $19.7 million, and $21.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.